Antiviral stilbene 1,2-diamines prevent initiation of hepatitis C virus RNA replication at the outset of infection

Journal of Virology

Volumn 85, Issue 11, 2011, Pages 5513-5523

  Gastaminza, Pablo ^a   Pitram, Suresh M ^a   Dreux, Marlene ^a   Krasnova, Larissa B ^a   Whitten Bauer, Christina ^a   Dong, Jiajia ^a   Chung, Josan ^a   Fokin, Valery V ^a   Sharpless, K Barry ^a   Chisari, Francis V ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAMINE DERIVATIVE; NONSTRUCTURAL PROTEIN 5A; STILBENE 1,2 DIAMINE DERIVATIVE; STILBENE OXIDE; UNCLASSIFIED DRUG; VIRUS RNA;

ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; PROTEIN TARGETING; RNA REPLICATION; STRUCTURE ACTIVITY RELATION; SYNTHESIS; VIRUS ENTRY; VIRUS INHIBITION; VIRUS TRANSCRIPTION;

ANTIVIRAL AGENTS; CELL LINE; CELL SURVIVAL; DIAMINES; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, VIRAL; HEPACIVIRUS; HEPATOCYTES; HUMANS; MICROBIAL SENSITIVITY TESTS; RNA, VIRAL; STILBENES; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

HEPATITIS C VIRUS;

EID: 79956076608     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02116-10     Document Type: Article

References (65)

1. Appel, N., et al. 2008. Essential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assembly. PLoS Pathog. 4:e1000035.
2. Bartenschlager, R., and V. Lohmann. 2000. Replication of hepatitis C virus. J. Gen. Virol. 81(Pt. 7):1631-1648.
3. Bartosch, B., et al. 2003. In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc. Natl. Acad. Sci. U. S. A. 100:14199-14204.
4. Bartosch, B., J. Dubuisson, and F. L. Cosset. 2003. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J. Exp. Med. 197:633-642.
5. Berger, K. L., et al. 2009. Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication. Proc. Natl. Acad. Sci. U. S. A. 106:7577-7582.
6. Bernhardt, G., H. Reile, H. Birnbock, T. Spruss, and H. Schonenberger. 1992. Standardized kinetic microassay to quantify differential chemosensitivity on the basis of proliferative activity. J. Cancer Res. Clin. Oncol. 118: 35-43.
7. Blanchard, E., et al. 2006. Hepatitis C virus entry depends on clathrinmediated endocytosis. J. Virol. 80:6964-6972.
8. Blight, K. J., A. A. Kolykhalov, and C. M. Rice. 2000. Efficient initiation of HCV RNA replication in cell culture. Science 290:1972-1975.
9. Carroll, S. S., et al. 2003. Inhibition of hepatitis C virus RNA replication by 2'-modified nucleoside analogs. J. Biol. Chem. 278:11979-11984.
10. Chang, K. S., J. Jiang, Z. Cai, and G. Luo. 2007. Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture. J. Virol. 81:13783-13793.
11. Cho, N. J., et al. 2010. Identification of a class of HCV inhibitors directed against the nonstructural protein NS4B. Sci. Transl. Med. 2:15ra6.
12. Dreux, M., P. Gastaminza, S. F. Wieland, and F. V. Chisari. 2009. The autophagy machinery is required to initiate hepatitis C virus replication. Proc. Natl. Acad. Sci. U. S. A. 106:14046-14051.
13. Egger, D., et al. 2002. Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J. Virol. 76:5974-5984.
14. Fridell, R. A., D. Qiu, C. Wang, L. Valera, and M. Gao. 2010. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob. Agents Chemother. 54:3641-3650.
15. Friebe, P., J. Boudet, J. P. Simorre, and R. Bartenschlager. 2005. Kissingloop interaction in the 3' end of the hepatitis C virus genome essential for RNA replication. J. Virol. 79:380-392.
16. Friebe, P., V. Lohmann, N. Krieger, and R. Bartenschlager. 2001. Sequences in the 5' nontranslated region of hepatitis C virus required for RNA replication. J. Virol. 75:12047-12057.
17. Gao, M., et al. 2010. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465:96-100.
18. Gastaminza, P., et al. 2008. Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. J. Virol. 82:2120-2129.
19. Gastaminza, P., et al. 2010. Ultrastructural and biophysical characterization of hepatitis C virus particles produced in cell culture. J. Virol. 84:10999-11009.
20. Gastaminza, P., et al. 4 February 2010. Inhibitors of hepatitis C virus infection. PCT/US2009/052147.
21. Gastaminza, P., S. B. Kapadia, and F. V. Chisari. 2006. Differential biophysical properties of infectious intracellular and secreted hepatitis C virus particles. J. Virol. 80:11074-11081.
22. Gastaminza, P., C. Whitten-Bauer, and F. V. Chisari. 2010. Unbiased probing of the entire hepatitis C virus life cycle identifies clinical compounds that target multiple aspects of the infection. Proc. Natl. Acad. Sci. U. S. A. 107:291-296.
23. Hoh, A., K. Maier, and R. M. Dreher. 1987. Multilayered keratinocyte culture used for in vitro toxicology. Mol. Toxicol. 1:537-546.
24. Honda, M., M. R. Beard, L. H. Ping, and S. M. Lemon. 1999. A phylogenetically conserved stem-loop structure at the 5' border of the internal ribosome entry site of hepatitis C virus is required for cap-independent viral translation. J. Virol. 73:1165-1174.
25. Hoofnagle, J. H. 2002. Course and outcome of hepatitis C. Hepatology 36:S21-S29.
26. Huang, H., et al. 2007. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc. Natl. Acad. Sci. U. S. A. 104:5848-5853.
27. Hughes, M., S. Griffin, and M. Harris. 2009. Domain III of NS5A contributes to both RNA replication and assembly of hepatitis C virus particles. J. Gen. Virol. 90:1329-1334.
28. Jiang, J., and G. Luo. 2009. Apolipoprotein E but not B is required for the formation of infectious hepatitis C virus particles. J. Virol. 83:12680-12691.
29. Jones, C. T., C. L. Murray, D. K. Eastman, J. Tassello, and C. M. Rice. 2007. Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus. J. Virol. 81:8374-8383.
30. Jones, D. M., A. H. Patel, P. Targett-Adams, and J. McLauchlan. 2009. The hepatitis C virus NS4B protein can trans-complement viral RNA replication and modulates production of infectious virus. J. Virol. 83:2163-2177.
31. Kaito, M., et al. 1994. Hepatitis C virus particle detected by immunoelectron microscopic study. J. Gen. Virol. 75(Pt. 7):1755-1760.
32. Kolb, H. C., M. G. Finn, and K. B. Sharpless. 2001. Click chemistry: diverse chemical function from a few good reactions. Angew. Chem. Int. Ed. Engl. 40:2004-2021.
33. Koutsoudakis, G., et al. 2006. Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J. Virol. 80:5308-5320.
34. Krieger, N., V. Lohmann, and R. Bartenschlager. 2001. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J. Virol. 75:4614-4624.
35. Li, X., et al. 1995. Identification of hepatitis C virus by immunoelectron microscopy. J. Viral Hepat. 2:227-234.
36. Liang, T. J., B. Rehermann, L. B. Seeff, and J. H. Hoofnagle. 2000. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann. Intern. Med. 132:296-305.
37. Lindenbach, B. D., et al. 2005. Complete replication of hepatitis C virus in cell culture. Science 309:623-626.
38. Lohmann, V., et al. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110-113.
39. Ma, Y., J. Yates, Y. Liang, S. M. Lemon, and M. Yi. 2008. NS3 helicase domains involved in infectious intracellular hepatitis C virus particle assembly. J. Virol. 82:7624-7639.
40. Macdonald, A., K. Crowder, A. Street, C. McCormick, and M. Harris. 2004. The hepatitis C virus NS5A protein binds to members of the Src family of tyrosine kinases and regulates kinase activity. J. Gen. Virol. 85:721-729.
41. Macdonald, A., and M. Harris. 2004. Hepatitis C virus NS5A: tales of a promiscuous protein. J. Gen. Virol. 85:2485-2502.
42. Maillard, P., et al. 2001. Nonenveloped nucleocapsids of hepatitis C virus in the serum of infected patients. J. Virol. 75:8240-8250.
43. Masaki, T., et al. 2008. Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles. J. Virol. 82:7964-7976.
44. Miyanari, Y., et al. 2007. The lipid droplet is an important organelle for hepatitis C virus production. Nat. Cell Biol. 9:1089-1097.
45. Moradpour, D., F. Penin, and C. M. Rice. 2007. Replication of hepatitis C virus. Nat. Rev. Microbiol. 5:453-463.
46. Murray, C. L., C. T. Jones, and C. M. Rice. 2008. Architects of assembly: roles of Flaviviridae non-structural proteins in virion morphogenesis. Nat. Rev. Microbiol. 6:699-708.
47. Murray, C. L., C. T. Jones, J. Tassello, and C. M. Rice. 2007. Alanine scanning of the hepatitis C virus core protein reveals numerous residues essential for production of infectious virus. J. Virol. 81:10220-10231.
48. Nahmias, Y., et al. 2008. Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin. Hepatology 47:1437-1445.
49. Neyts, J. 2006. Selective inhibitors of hepatitis C virus replication. Antiviral Res. 71:363-371.
50. Patel, K., and J. G. McHutchison. 2004. Initial treatment for chronic hepatitis C: current therapies and their optimal dosing and duration. Cleve. Clin. J. Med. 71(Suppl. 3):S8-S12.
51. Pedersen, I. M., et al. 2007. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 449:919-922.
52. Penin, F., J. Dubuisson, F. A. Rey, D. Moradpour, and J. M. Pawlotsky. 2004. Structural biology of hepatitis C virus. Hepatology 39:5-19.
53. Prince, A. M., T. Huima-Byron, T. S. Parker, and D. M. Levine. 1996. Visualization of hepatitis C virions and putative defective interfering particles isolated from low-density lipoproteins. J. Viral Hepat. 3:11-17.
54. Roingeard, P., C. Hourioux, E. Blanchard, D. Brand, and M. Ait-Goughoulte. 2004. Hepatitis C virus ultrastructure and morphogenesis. Biol. Cell 96:103-108.
55. Steinmann, E., et al. 2007. Hepatitis C virus p7 protein is crucial for assembly and release of infectious virions. PLoS Pathog. 3:e103.
56. Street, A., A. Macdonald, K. Crowder, and M. Harris. 2004. The hepatitis C virus NS5A protein activates a phosphoinositide 3-kinase-dependent survival signaling cascade. J. Biol. Chem. 279:12232-12241.
57. Tan, S. L., et al. 1999. NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling. Proc. Natl. Acad. Sci. U. S. A. 96:5533-5538.
58. Tellinghuisen, T. L., K. L. Foss, and J. Treadaway. 2008. Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. PLoS Pathog. 4:e1000032.
59. Trestard, A., et al. 1998. Ultrastructural and physicochemical characterization of the hepatitis C virus recovered from the serum of an agammaglobulinemic patient. Arch. Virol. 143:2241-2245.
60. Tscherne, D. M., et al. 2006. Time-and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J. Virol. 80:1734-1741.
61. Wakita, T., et al. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11:791-796.
62. Yi, M., Y. Ma, J. Yates, and S. M. Lemon. 2009. Trans-complementation of an NS2 defect in a late step in hepatitis C virus (HCV) particle assembly and maturation. PLoS Pathog. 5:e1000403.
63. Zech, B., et al. 2003. Identification and characterization of amphiphysin II as a novel cellular interaction partner of the hepatitis C virus NS5A protein. J. Gen. Virol. 84:555-560.
64. Zhong, J., et al. 2005. Robust hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. U. S. A. 102:9294-9299.
65. Zhong, J., et al. 2006. Persistent hepatitis C virus infection in vitro: coevolution of virus and host. J. Virol. 80:11082-11093.